Delpazolid is primarily investigated for its potential use as an antibacterial agent, particularly in the treatment of drug-resistant bacterial infections. Its application is focused on combating multidrug-resistant tuberculosis (MDR-TB) and other Gram-positive bacterial infections. Delpazolid works by inhibiting bacterial protein synthesis, making it effective against strains that are resistant to conventional antibiotics. Clinical trials are ongoing to evaluate its efficacy, safety, and optimal dosing regimens. If proven successful, it could become a critical component in addressing the global challenge of antibiotic resistance, particularly in TB-endemic regions.